BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Phase 1/2a trial of BNT324/DB-1311 in solid tumors showed a 32.4% unconfirmed objective response rate and 82.4% disease control rate. BNT324/DB-1311 showed a manageable safety profile across all ...

BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line." The analyst in question also hiked its price target to ...

BioNTech SE ( ($BNTX) ) has provided an update. On December 18, 2025, BioNTech SE announced it had closed its acquisition of CureVac N.V., ...

We have seen 119 institutional investors add shares of $BNTX stock to their portfolio, and 192 decrease their positions in their most recent quarter.

Shares of BioNTech SE – ADR (NASDAQ:BNTX) fell 5.7% to $115.84 on Monday, part of a broader decline in vaccine stocks triggered by Moderna's updated revenue guidance for 2025, which fell below analyst ...

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other German stocks. In Germany, ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company reported earnings per share of €1.08 compared to Wall Street’s estimate of 44 ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where BioNTech SE (NASDAQ:BNTX) stands against other ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

BioNTech (NASDAQ:BNTX) announced Tuesday that its mRNA-based cancer therapy BNT111, in combination with Regeneron’s (NASDAQ:REGN) anti-PD-1 therapy, Libtayo (cemiplimab), succeeded in a Phase 2 trial ...